

# Long-term management of patients with urea cycle disorders

Gerard T. Berry, MD, and Robert D. Steiner, MD

The long-term treatment of patients with urea cycle disorders (UCDs) includes diet treatment and use of specific medications. Guidelines are provided for patients with a severe phenotype. However, treatment must be tailored for each individual, especially with regard to residual enzyme function and in vivo metabolic capacity. This will be reflected in tests used for monitoring therapy that should be performed on a periodic basis. The goal of therapy is to eliminate chronic complications, a laudable but rarely attainable goal. Sick-day rules are discussed. Chronic management also includes diverse services that are essential to the success of the metabolic program. These include neurologic and developmental evaluations, feeding team evaluation and therapy, physical and occupational therapies, speech therapy, school and educational services, social service intervention, psychological services, and genetic counseling. (J Pediatr 2001;138:S56-S61)

The long-term treatment of patients with urea cycle disorders involves the use of a low-protein diet, supplementation with certain amino acids, and administration of organic compounds to augment waste nitrogen excretion.<sup>1-8</sup> Optimal care, however, necessitates the use of a comprehensive long-term management program that anticipates

and responds to a diverse array of needs and complications. The items covered in the treatment of the patients are outlined in Table I.

The list of UCDs is shown in Table II. The most common UCD is ornithine transcarbamylase deficiency.<sup>1</sup> Inherited as an X-linked trait, it affects both males and females. The phenotype is extremely variable, not only because of random X chromosome inactivation in females but also because of many different types of OTC gene mutations and modifying factors such as puberty, pregnancy, labor and delivery, and environmental factors. The spectrum of disease expression ranges from the catastrophically ill 2-day-old boy with an extremely severe form of the disease to the previously healthy adult woman with postpartum hyperammonemia.<sup>1,9,10</sup> The long-term management of each of these forms of OTC deficiency may be different. It is important to be mindful that the type of

low-protein diet and amount of medication must be tailored to each individual patient's phenotype and needs.<sup>9</sup> However, in this article we restrict our discussion of treatment to the UCD with a severe phenotype. Also, because the therapy for carbamylphosphate synthetase deficiency is similar to that of OTC deficiency,<sup>1</sup> treatment of both will be addressed as one. The rest of the UCDs will be addressed separately. CPS, argininosuccinate synthetase, argininosuccinate lyase, and arginase deficiencies are all inherited as autosomal recessive traits.<sup>1</sup>

ASL	Argininosuccinic acid lyase
ASS	Argininosuccinic acid synthetase
CPS	Carbamyl phosphate synthetase I
OTC	Ornithine transcarbamylase
UCD	Urea cycle disorder

## DIET

The low-protein diet and medications used in the treatment of infants with each of the UCDs are shown in Table III and are based on the recommended treatment as outlined, at least in part, in the book entitled *Metabolic and Molecular Basis of Inherited Diseases*.<sup>1</sup> However, it is important to note that these doses are recommended for severely affected patients and are not suitable for all patients. The treatment must be tailored to the needs of the patient as reflected in the growth rate, plasma ammonia, and amino acid levels and ancillary tests such as blood counts and serum albumin. The biochemical and nutritional rationales that are used for 2 representative patients are depicted in the flow diagrams in


*From the Divisions of Human Genetics and Molecular Biology and Endocrinology and Diabetes, Department of Pediatrics, University of Pennsylvania School of Medicine, The Children's Hospital of Philadelphia, Pennsylvania, and the Metabolic Clinic, Child Development and Rehabilitation Center, Doernbecher Children's Hospital, Oregon Health Sciences University, Portland, Oregon.*

Reprint requests: Gerard T. Berry, MD, Room 402 Abramson Research Center, Department of Pediatrics, The Children's Hospital of Philadelphia, 34<sup>th</sup> & Civic Center Blvd, Philadelphia, PA 19104-4399.

Copyright © 2001 by Mosby, Inc.

0022-3476/2001/\$35.00 + 0 9/0/111837

doi:10.1067/mpd.2001.111837



**Fig 1.** Maintenance therapy and whole body nitrogen economy in patients with severe UCDs. Six-month-old infant with OTC deficiency. \*Forty percent to 45% used for waste nitrogen production. \*\*Sixteen percent of protein and 11.5% of amino acids are nitrogen. \*\*\*Formula weight: sodium phenylbutyrate = 186. ☆This calculation does not take into account the fact that the nitrogen atom in glutamate derived from essential amino acid catabolism can be reused for synthesis of nonessential amino acids necessary for protein synthesis.

Figs 1 and 2. Please note that the patient whose treatment is depicted in Fig 2 is a 6-year-old child, not an infant. This child serves to illustrate how the protein intake, medication dosage, and partitioning of nitrogen differs according to disease type and age.

In most instances only the broad ranges are given. The first principle is that the amount of whole protein that can be given to the patient will depend on the enzyme deficiency and age. With severe OTC deficiency, it is necessary to restrict dietary protein intake to an amount that is inadequate to permit growth in infancy; the remaining amount of nitrogen must be delivered as essential amino acids. This is analogous to increasing the biologic value of the protein. Therefore the total amount of nitrogen ingested per day can be reduced below the threshold necessary for growth. The types and amounts of medications will also vary but primarily are dependent on the enzyme defect. In OTC and CPS deficiencies, citrulline therapy is used to restore body arginine pools for protein synthesis. Arginine may be used instead of citrulline, but the drawback is that the waste nitrogen atom from aspartate used in the ASS reaction is not used. However, in ASL deficiency

arginine is exclusively used not only to maintain adequate arginine levels but also to increase production of argininosuccinate and thereby enhance urinary excretion of waste nitrogen in the form of argininosuccinate. This works much better for ASL than for ASS deficiency, because argininosuccinate, unlike citrulline, is essentially filtered by the kidney and excreted in urine without being reabsorbed.

## CLINICAL AND LABORATORY MONITORING

Clinical and laboratory monitoring of each patient is important to the success of the long-term management. The critical parameters in clinical monitoring of therapy are shown in Table IV. These include the growth parameters, weight, height, and head circumference, the developmental and neurologic assessments, and the examination of the liver. In severe ASL deficiency the liver is usually chronically enlarged despite adequate treatment.<sup>1</sup> Some patients may even have cirrhosis. The key tests for laboratory monitoring of therapy are shown in Table V. This testing includes the quantitation


**Table I.** Long-term treatment of patients with UCDs

Low-protein diet and medications
Acute episodes
Elective surgery
Neurologic and developmental evaluations
Feeding team evaluation and therapy
Physical and occupational therapies
Speech therapy
School and education services
Social services
Psychologic services
Genetic counseling

**Table II.** Urea cycle disorders

OTC deficiency
CPS deficiency
ASS deficiency
ASL deficiency
Arginase deficiency
N-acetylglutamate synthase deficiency

of plasma ammonia, plasma amino acids, and in some instances, urine orotate. A complete blood count with a differential serum chemistry panel screen including liver function tests



**Fig 2.** Maintenance therapy and whole body nitrogen economy in patients with severe UCDs. Six-year-old child with ASL deficiency. \*Molecular weight arginine = 174. †Assuming 100% of ASA is filtered and excreted.

**Table III.** Treatment of infants with UCDs

UCD	Diet		Medications		
	Protein (g/kg/d)	Essential Amino Acids (g/kg/d)	Sodium phenyl- butyrate (g/kg/d)	Arginine (g/kg/d)	Citrulline (g/kg/d)
OTC deficiency					
CPS deficiency	0.7	0.7	0.45-0.60 (9.9-13.0)*	—	0.17 (3.8)*
ASS deficiency	1.5 – 2.0	—	0.45-0.60	0.4 – 0.7 (8.8-15.4)*	—
ASL deficiency	1.5 – 2.0	—	0.45-0.60	0.4 – 0.7	—
Arginase deficiency†	0.7	0.7	0.30-0.60	—	—

\* (g/m<sup>2</sup>/d)  
† N.B. data on treatment of infants with arginase deficiency are not available, especially for prospective use in asymptomatic newborns.

**Table IV.** Clinical monitoring of therapy.

Weight, height, and head circumference
Developmental assessment
Neurologic assessment
Liver examination

**Table V.** Laboratory monitoring of therapy

Plasma ammonia
Plasma amino acid quantitation
Urine orotate

the whole body waste nitrogen burden.<sup>1,11,12</sup> The finding of both an elevated plasma ammonia and glutamine level indicates that body ammonia is elevated and the patient is at risk for hyperammonemic encephalopathy.<sup>1</sup> The other amino acids that may be elevated in plasma include alanine, glycine, glutamate, asparagine, aspartate, and lysine. Except in arginase deficiency, plasma arginine may be decreased in the patient with inadequate treatment with arginine or citrulline. The latter may be low in some patients with OTC or CPS deficiency despite therapy. Occasionally, levels of the essential amino acids and, most important, the branched-chain amino acids, leucine, isoleucine, and valine, may fall below the normal range because of the use of a strict low-protein diet. It is important not to allow such deficiency to remain chronic and severe; otherwise, a nutritional deficiency state may ensue. Manifestations may include poor growth, anemia, rash, and hypoalbuminemia.

The biochemical targets for optimal UCD control are noted in Table VI. These include a plasma ammonia level of <40 μmol/L, a plasma glutamine level of <1000 μmol/L, normal plasma levels of alanine, glycine, lysine, and arginine, and no subnormal concentration of any of the essential amino acids. When arginine therapy is used, the serum levels will vary, depending

and urinalysis should be obtained on a yearly basis. Every 5 to 10 years each patient should be screened specifically for iron deficiency, vitamin B<sub>12</sub> deficiency, or both, because of the low-protein, low-meat intake diet.

The goal of treatment is to maintain normal levels of plasma ammonia

through the use of the low-protein diet and medication while allowing for normal growth. As the body's burden of waste nitrogen increases, certain amino acid levels will rise, along with or preceding the rise in plasma ammonia. The most prominent is glutamine, the amino acid that is used to monitor

**Table VI.** Biochemical targets for optimal UCD control

Plasma ammonia <40  $\mu\text{mol/L}$   
Plasma glutamine <1000  $\mu\text{mol/L}$   
Normal plasma levels of alanine, glycine, lysine, and arginine (except arginase deficiency)  
No subnormal concentrations of essential amino acids (eg, leucine, isoleucine, valine)  
Normal urinary orotate excretion (<3  $\mu\text{mol/mmol}$  creatinine)  
Normal plasma protein concentrations (eg, albumin)

These goals are not always attainable, or even appropriate in every patient. Treatment **must** be individualized.

**Table VII.** Chronic complications in patients on UCD therapy

Poor growth  
Developmental delay  
Learning problems  
Speech disorder  
ADHD  
Mental retardation  
Spasticity  
Seizure disorder  
Hepatomegaly

*ADHD*, Attention deficit hyperactivity disorder.

on the dosage schedule (usually 4-times daily) and timing of the blood sample, but the per-dose values should be <200  $\mu\text{mol/L}$ . Some patients appear to maintain good metabolic control with higher glutamine levels, that is, >1000  $\mu\text{mol/L}$  (personal communication, J.V. Leonard). Ideally, the urinary orotate excretion will be <3  $\mu\text{mol/mmol}$  creatinine. Plasma concentrations of proteins such as albumin should be in the normal range. Measurement of plasma prealbumin may be necessary at times to ascertain the presence of an incipient protein deficiency. It is important to note that citrulline levels will always be markedly increased in patients with ASS deficiency, and both argininosuccinate and citrulline may be elevated in patients with ASL deficiency. It is almost impossible to achieve chronic normal levels of arginine in patients with arginase deficiency while on a protein-restricted diet, even when supplemented with an essential amino acid powder mixture.

## COMPLICATIONS OF UCD THERAPY

The chronic complications that may be seen in patients receiving UCD therapy are shown in Table VII. These include poor growth, developmental

delay, learning problems, speech disorder, attention deficit hyperactivity disorder, mental retardation, spasticity as in cerebral palsy, seizure disorder, and hepatomegaly with and without liver function test abnormalities.<sup>1,2,15,14</sup> It is important to note that normal variant short stature such as genetic short stature and constitutional delay of growth and puberty may also occur in patients with UCDs. Whether the latter condition is more prevalent in the UCD population is unknown. Many of the previously described complications may be a consequence of hyperammonemic coma in the newborn period or later, after an acute intermittent illness. In addition, some patients may have been chronically intoxicated because of a delay in diagnosis. This type of patient can present in late infancy or childhood with progressive psychomotor retardation or with what appears to be a progressive neurodegenerative disease such as with arginase deficiency. After the hyperammonemia is corrected or the disease process is stabilized, all of the sequelae such as learning problems, speech defect, cerebral palsy, and seizure disorders will need to be treated, as with any child without a UCD. Patients with ASL deficiency in particular may have developmental delay and seizures despite adequate metabolic control and the absence of a historical episode of hyperammonemic coma. Sometimes poor

disease control may result in chronic hepatomegaly with increased accumulation of fat and glycogen in the liver, fibrosis, and abnormal liver function tests. It usually remits after stabilization of the hyperammonemia. As noted previously, this is not the case with ASL deficiency, especially with the neonatal-onset variety.

The intercurrent illnesses or an acute episode of decompensation associated with hyperammonemia must be treated as delineated by Brusilow et al.<sup>6</sup> This may include the use of intravenous sodium phenylacetate, sodium benzoate, and arginine hydrochloride. Hemodialysis therapy may also be necessary. If the patient is not comatose, enteral administration of medications and cessation of protein intake may be effective. Parents are to be instructed in the signs and symptoms of hyperammonemia such as anorexia, vomiting, altered behavior, headache, visual disturbances, ataxia, lethargy, and seizures that may indicate acute hyperammonemia. These may occur during a viral illness or after ingestion of a large amount of dietary protein. If a patient is ill because of an acquired illness but the plasma ammonia level is <100  $\mu\text{mol/L}$  (approximately 3 times the upper range of normal), the family should introduce a sick-day routine.<sup>15</sup> This consists of a decrease, or more commonly a cessation, of protein intake while nonprotein calories are given often in the form

of fruit juices, or even better, the Ross Prophree or Mead-Johnson 80056 formula suspensions. The ammonia scavenging medications should be administered during these periods, and dosages can be increased by approximately 50% if warranted by the clinical findings.

## UCD AND SURGERY

If patients require elective surgery, they should be admitted to the hospital on the day before surgery. At this time the plasma ammonia and amino acid levels should be checked to ensure that the patient is not in a decompensated state prior to surgery. Before surgery, when the patient is no longer allowed to eat or drink, an intravenous catheter should be placed to deliver fluids, glucose, and electrolytes at a maintenance rate. This will prevent fasting-induced catabolism and its associated hyperammonemia. In older children and adolescents, the use of a 10% glucose solution may produce hyperglycemia to a degree sufficient to induce an osmotic diuresis and volume contraction. For these instances a 5% glucose solution should be used. Patients may also need to receive the UCD medications before, during, and after the procedure. Depending on the severity of the enzyme deficiency and the nature of the surgery, plasma ammonia levels should be monitored before, during, and after the operation, even in the recovery room. If the procedure is a long one such as an orthopedic scoliosis repair, it may be necessary to administer glucose and Intralipid, with total parenteral nutrition (the equivalent of a low-protein diet) along with intravenous sodium phenylacetate, sodium benzoate, and arginine hydrochloride during the operation.

The rest of the services outlined in Table I should be delivered to the patients and their families. There are exceptions, but the broad and comprehensive approach to care is especially important for the patient with neona-

tal-onset disease. Many of the patients with OTC and CPS deficiencies are so severely affected that the medical therapies outlined previously are only temporizing measures until liver transplantation can be performed in the first year of life.<sup>16,17</sup> The delivery of chronic care to a patient with this kind of special needs requires a multidisciplinary approach.

## REFERENCES

1. Brusilow SW, Horwich AL. Urea cycle enzymes. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill Information Services Co; 1995. p. 1187-232.
2. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. *Adv Pediatr* 1996;43:127-70.
3. Bachmann C. Urea cycle disorders. In: Fernandes J, Saudubray J-M, Tada K, editors. Inborn metabolic diseases. 1990. p. 211-28.
4. Batshaw ML, Thomas GH, Brusilow SW. New approaches to the diagnosis and treatment of inborn errors of urea synthesis. *Pediatrics* 1981;68:290-7.
5. Batshaw ML, Brusilow S, Waber L, Blom W, Brubakk AM, Burton BK, et al. Treatment of inborn errors of urea synthesis: activation of alternative pathways of urea synthesis. *N Engl J Med* 1982;306:1387-92.
6. Brusilow SW, Danney M, Waber LJ, Batshaw M, Burton B, Levitsky L, et al. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. *N Engl J Med* 1984;310:1630-4.
7. Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. *N Engl J Med* 1996;335:855-9.
8. Feillet F, Leonard JV. Alternative pathway therapy for urea cycle disorders. *J Inherit Metab Dis* 1998;21:101-11.
9. Brusilow SW, Finkelstein J. Restoration of nitrogen homeostasis in a man with ornithine transcarbamylase deficiency. *Metabolism* 1993;42:1336-9.
10. Arn PH, Hauser ER, Thomas GH, Herman G, Hess D, Brusilow SW. Hyperammonemia in women with a mutation at the ornithine carbamyltransferase locus. A cause of postpartum coma. *N Engl J Med* 1990;322:1652-5.
11. Maestri NE, McGowan KD, Brusilow SW. Plasma glutamine concentration: a guide to the management of urea cycle disorders. *J Pediatr* 1992;121:259-61.
12. Tuchman M, Yudkoff M. Blood levels of ammonia and nitrogen scavenging amino acids in patients with inherited hyperammonemia. *Mol Genet Metab* 1999;66:10-5.
13. Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED. Neurologic outcome in children with inborn errors of urea synthesis: outcome of urea-cycle enzymopathies. *N Engl J Med* 1984;310:1500-5.
14. Uchino T, Endo F, Matsuda I. Neurodevelopmental outcome of long-term therapy of urea cycle disorders in Japan. *J Inherit Metab Dis* 1998;21:151-9.
15. Dixon MA, Leonard JV. Intercurrent illness in inborn errors of intermediary metabolism. *Arch Dis Child* 1992;67:1387-91.
16. Whittington PF, Alonso EM, Boyle JT, Molleston JP, Rosenthal P, Emond JC, et al. Liver transplantation for the treatment of urea cycle disorders. *J Inherit Metab Dis* 1998;21:112-8.
17. Saudubray JM, Touati G, Delonlay P, Jouvet P, Narcy C, Laurent J, et al. Liver transplantation in urea cycle disorders. *Eur J Pediatr* 1999;158:S55-9.

## LONG-TERM MANAGEMENT DISCUSSION

### *Coordinator Role*

It was agreed that there is a need to establish a coordinator to oversee all aspects of the treatment of a patient with UCD, so that progress over time is properly reviewed.

### *Amino Acid Levels*

Maintenance is aimed at balancing the amino acid pools. To achieve this, a range of proteins from different sources should be taken by the patient. Determination of amino acid levels should be made with a blood sample taken 2 hours after a meal. The amino acid levels should be as low as possible without being subnormal, providing growth is not compromised.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.